tbuckley/cabot-search huggingface dataset:
Antineoplastic Effect of the Combination of 2,3-Dihydro-lH-pyrazole[2,3a]imidazole plusDeoxyadenosine/erythro-9-(2-hydroxyl-3-nonyl)adenine in Mice with L1210 Leukemia Cells
Authors: M Matsumoto, G Weckbecker, J G Cory
Journal: Cancer Communications (1990)

Administration of 2,3-dihydro-1H-pyrazole[2,3a]imidazole (IMPY, 150 mg/kg) followed 8 hr later by injection of deoxyadenosine/erythro-9-(2-hydroxyl-3-nonyl)adenine (dAdo/EHNA, 175 mg/17.5 mg/kg) on days 2, 3, 6, and 7 increased the mean survival time of L1210 tumor bearing mice (210%). The sequential treatment was more efficacious than the simultaneous administration of these drugs. Administration of IMPY or dAdo/EHNA, alone, at the same doses as in the combination, did not prolong the life-span of tumor bearing mice. To determine the basis for the increased survival due to the sequential treatment with IMPY and dAdo/EHNA, cell cycle analysis and deoxyribonucleoside triphosphate concentrations were measured. Cytotoxicity of IMPY and dAdo/EHNA is known to be achieved through the inhibition of ribonucleotide reductase. IMPY is a specific inhibitor of the nonheme-iron subunit of ribonucleotide reductase, whereas deoxyadenosine in the presence of the adenosine deaminase inhibition, EHNA, is converted to deoxyadenosine 5'-triphosphate (dATP), which is a specific inhibitor of the effector-binding-subunit of ribonucleotide reductase. Our studies showed that L1210 cells accumulated in early S-phase, whereas intracellular dATP and deoxyguanosine triphosphate (dGTP) pools were depleted 8 hr after IMPY administration. dAdo/EHNA administration 8 hr after IMPY injection caused an increase in the intracellular concentration of dATP while maintaining the depletion of the dGTP pool and prolonged the S-phase as compared to the administration of IMPY alone.
Early detection of gastric cancer.
Authors: E Monge
Journal: BMJ (1990)

Objective-To see whether investigation of dys- peptic patients aged over 40 after their first consulta- tion with the general practitioner would increase the proportions with early and operable gastric cancers.Design-Prospective study of gastric cancer in dyspeptic patients aged over 40 from a defined population.Setting-10 General practices (six in central Birmingham, four in Sandwell); the Queen Elizabeth Hospital, Birmingham; and Sandwell District General Hospital.Patients-2659 Patients aged 40 or over referred with dyspepsia.Main outcome measure-Increase in early and operable gastric cancers detected in middle aged patients with dyspepsia.Results-Disease was identified in 1992 patients (75%).Fifty seven were found to have gastric cancer, 36 being treated by potentially curative resection, including 15 with early cancer.Conclusions-The investigation of dyspeptic patients over 40 at first attendance can increase the proportion of early gastric cancers detected to 26% and the proportion of operable cases to 63%.Such a policy has the potential to reduce mortality from gastric cancer in the population.
Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3
Authors: K Geissler, C Peschel, D Niederwieser, H Strobl, J Goldschmitt, L Ohler, P Bettelheim, P Kahls, C Huber, K Lechner, P Hocker, K Kolbe
Journal: Blood (1996)
PWE-073 Metabonomics and it–s use in inflammatory bowel disease (ibd): a systematic review
Authors: N Ding, N Yassin, A Hart
Journal: Gut (2015)

<h3>Introduction</h3> The management of IBD remains a challenge. Correct diagnosis is vital for the optimal management of the disease. Metabonomic studies have been used for biomarker identification for the diagnosis of IBD and differentiating between Crohn–s disease (CD) and ulcerative colitis (UC). Ideal biomarkers are required for the prediction and personalisation of treatment. We performed a systematic review aiming to identify relevant biomarkers in multiple biofluids from IBD patients and the laboratory techniques which are used for the analysis of the metabolites. <h3>Method</h3> A systematic review of the literature was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Two independent reviewers searched all publications from Pubmed, Cochrane and EMBASE using MESH terms and keyword searches with "metabonomics, metabolomics, IBD, Crohn–s disease, ulcerative colitis, NMR, GC-MS, lipidomics and LCMS". <h3>Results</h3> The initial search identified 128 articles, of which 48 were screened for the inclusion and exclusion criteria and 26 were finally included for the analysis. The total number of patients was 1552 of which 745 were CD and 784 UC. The biofluids were urine, serum and faeces. These were analysed using three labarotory techniques: Nuclear magnetic resonance (NMR), Gas chromatography-Mass Spectrometry (GC-MS) and Liquid Chromatography- Mass Spectrometry (LC-MS); Table 1. Urine Six studies have examined urinary metabolites with a total of 188 CD and 211 UC patients. All used NMRspectroscopy. All studies were designed with the aim of diagnostic biomarker identification. Faeces Six studies analysed metabolites from faeces using NMR, LC-MS and GC-MS. Total number of patients were 164 CD and 141 UC. The main aim of 4/6 studies was biomarker identification of IBD. Two further studies used GC-MS and LC-MS to identify predictive biomarkers for flares of UC post-medical therapy due to the greater sensitivity of the techniques. Serum: Eight studies analysed serum using NMR and LC-MS. Total patients examined were 302 CD and 438 UC. The aims were to identify diagnostic biomarkers in addition to the prediction of treatment outcomes and monitoring disease activity. <h3>Conclusion</h3> Multiple specific metabolites have been identified in Crohn–s and ulcerative colitis. The techniques for identification are non-invasive, instant and can be used to create specific profiles for CD and UC. A prospective longitudinal study is required to identify prognostic markers and predictors of response to medical therapies. <h3>Disclosure of interest</h3> None Declared.
Internal Malignancy in Genetic Hemochromatosis
Authors: A E Bale
Journal: JNCI Journal of the National Cancer Institute (1986)

Journal Article Internal Malignancy in Genetic Hemochromatosis Get access Allen E. Bale, M.D. Allen E. Bale, M.D. Clinical Epidemiology Branch, Division of Cancer Etiology, National Cancer Institute, National Institutes of Health, Landow Building, Room 8C41, Public Health Service, U.S. Department of Health and Human Services, Bethesda, Maryland 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 76, Issue 6, June 1986, Pages 1260–1261, https://doi.org/10.1093/jnci/76.6.1260 Published: 01 June 1986
AB0969 The Role of Environmental Factors in Juvenile Idiopathic Arthritis
Authors: D. Dop, C.E. Niculescu, D. Bulucea
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Juvenile idiopatic arthritis (JIA) is an autoimmune disease caused by a complex combination of genetic and environmental factors. <h3>Objectives</h3> Our study tries to determine the impact of environmental factors on the onset and progression of JIA. <h3>Methods</h3> The multicenter study was retrospective and prospective, on a group of 173 Romanian JIA patients selected in accordance to the ILAR criteria and classification. The control group included 236 healthy children of similar age and ethnic background. The data was collected through a questionnaire handed to the parents. The parameters we looked for were: gestational age, weight at birth (under 3000 g, over 3000 g), maternal age, maternal smoking, repeated infections in the first 2 years of life, duration of breast feeding (less than 6 months, longer than 6 months). <h3>Results</h3> Breastfeeding for longer than 6 months was present in 41.61% JIA patients, as opposed to 68% in the control group (p=0.0052). Comparing the oligoarticular form to the systemic one, there were more children who had been breastfed (65.06% versus 23.07%; p=0.0207). Repeated infections in the first 2 years of life were present in 54.17% of the patients, as opposed to 37.28% in the control group (p=0.0487), and they were preponderant in the FR+ poliarticular form 89.36% (p=0.0432). No significant differences to the control group were determined for parameters such as gestational age, weight at birth, maternal age, maternal smoking. <h3>Conclusions</h3> The influence of environmental factors on JIA onset and evolution remains unknown. Extended studies are necessary in order to determine the impact of such factors on JIA. <h3>Disclosure of Interest</h3> None declared
Effect of haloperidol and apomorphine treatment on dopamine receptors in pituitary and striatum
Authors: W C Friend, G M Brown, G Jawahir, T Lee, P Seeman
Journal: American Journal of Psychiatry (1978)

Prompted by an interest in the similarity of brain and tuberoinfundibular systems, the authors studied butaclamol-specific neuroleptic and apomorphine binding in pituitary and striatum after chronic haloperidol and acute apomorphine treatment. Striatal binding increases but pituitary binding decreases in haloperidol-treated rats. Pituitary binding changes rapidly in response to apomorphine exposure and striatal binding does not. These findings suggest that factors influencing binding differ in these two tissues.
Recurrent Urinary Bladder Paraganglioma Detected on 68Ga DOTANOC PET/CT
Authors: Sampanna Jung Rayamajhi, Bhagwant Rai Mittal, Jaya Shukla, Rakhee Vatsa, Anish Bhattacharya, Arup K Mandal
Journal: Clinical Nuclear Medicine (2015)

Urinary bladder paraganglioma constitute only a small fraction of urinary bladder tumors. These rare tumors are well known for recurrences even after many years of surgery. Functional imaging with different radiotracers has been found to be useful to evaluate the extent, metastasis, and recurrence of paragangliomas. We report a case where Ga DOTANOC PET/CT successfully detected recurrence of a paraganglioma in the urinary bladder along with pelvic lymph nodal metastasis.
AB1024 A Rare Case of Neonatal Antiphospholipid Syndrome
Authors: T. Giani, A. Mauro, I. Pagnini, G. Simonini, F. Bertini, A. Marino, R. Cimaz
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Neonatal Antiphospholipid antibody syndrome (APS) is a rare clinical entity linked to the transplacental transfer of antiphospholipid antibodies (aPL). Additional risk factors such as asphyxia, sepsis, arterial or venous catheter, congenital thrombophylia are frequently associated, precipitating the thrombophylic action of aPL. <h3>Objectives</h3> We describe a case of neonatal thrombotic stroke associated with IgG (but not IgM) aPL. <h3>Methods</h3> A 6 month old Caucasian child presented to our clinic with a history of seizures, delayed psychomotor development, right hemiparesis and right homonymous hemianopsia. The family history was uncontributive. A placental abruption on the 3rd month of gestation and premature contractions in the second trimester were reported. The child was born at 38 weeks of gestational age with a natural childbirth, and a fetal APGAR index of 9/9. However the mother noticed a left facial hypotrophy since the first days of life, and described a progressively reduced use of his right arm. At 3 months of age the child developed a divergent strabismus, and recurrent partial seizures. <h3>Results</h3> Cerebral MRI at 6 months of age exhibited changes consistent with ischemic cerebral lesions in the left middle cerebral artery territory with a MR angiography showing a thinning caliber of this vessel. Heart ultrasound was unremarkable. Routine laboratory test including infectious serologies were normal or negative. Prothrombotic risk factors ie PT, APTT, fibrinogen, protein S, protein C, Lupus Anticoagulant, IgM Anticardiolipin antibodies and IgM β2 GP1 were negative or in normal range. IgG anticardiolipin were elevated at 17 U/ml (normal &lt;10), and IgG β2 GP1 were also positive at 59 U/ml (normal &lt;10). Molecular genetic testing demonstrated heterozygosity for G1691A factor V Leiden mutation. Subsequently, at the age of 9 months IgG anticardiolipin and β2 GP1 resulted negative. Testing for aPL was performed 6 months after the delivery in the mother and was negative. The child currently presents a refractory epilepsy and an abnormal neurological status with trunk hypotonia and global developmental delay. <h3>Conclusions</h3> aPL-related thrombosis is exceedingly rare In the neonatal period. The consequences depend on the type of organ and vessel involved, the vessel size and on the rapid or slow course of the thrombotic process. The most frequently described type of thrombotic events is deep venous thrombosis in the lower extremities, pulmonary embolism, and thrombotic complications in the central nervous system. aPL alone may not be sufficient to cause the ischemic damage, and others prothrombotic conditions are probably implicated. In our patient the heterozygosity for factor V Leiden mutation, placental abruption at the III month of pregnancy and premature contractions may have contributed to the thromboembolic disease in presence of maternal IgG aPL. <h3>Disclosure of Interest</h3> None declared
FRI0566 Ultrasound Demonstrates Tenosynovitis to be Frequent in RA Patients as Well as Being Responsive to Biologic Treatment
Authors: H.B. Hammer, L. Terslev, T.K. Kvien
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Ultrasound (US) (grey scale (GS) and power Doppler (PD)) is a sensitive tool for detection of tenosynovitis in patients with rheumatoid arthritis (RA). The extensor carpi ulnaris (ECU) and tibialis posterior (TP) tendons have previously been shown to be frequently inflamed in RA patients. Even so, only few of the US joint scores include these tendons in disease assessments. <h3>Objectives</h3> To explore the frequency of inflammatory involvement of ECU and TP tendons in patients with established RA and study their response to biologic treatment. <h3>Methods</h3> A total of 157 patients (83% women, 78% anti-CCP positive, mean (SD) age 52.4 (12.1) years with 11.2 (9.0) years of disease activity) were included. They were assessed at baseline when starting biologic treatment (infliximab (n=16); etanercept (n=59); adalimumab (n=8); certolizumab (n=13); golimumab (n=8); rituximab (n=37); tocilizumab (n=12); abatacept (n=4)) and after 1, 2, 3, 6 and 12 months with US, clinical (tender and swollen joints (of 28) and laboratory (ESR and CRP)) assessments. The ECU and TP tendons were examined bilaterally by US and scored semi-quantitatively 0-3 for GS and PD (one sonographer (HBH) using Siemens Antares, Excellence version, with a fixed optimal setting without upgrading during the study). The frequencies of tendon involvement at baseline as well as the sum scores of GS and PD at all examinations were calculated, and the changes in US sum scores from baseline were explored by paired samples T-test. <h3>Results</h3> At baseline, 57% of the patients had GS pathology at least unilaterally of the ECU tendons and 50% at least unilaterally of the TP tendons, while the presence of PD activity was 33% and 36%, respectively. Only 24% of the patients had no GS tenosynovitis in the ECU/TP tendons, and the sum scores for GS assessments were 1 in 17%, 2 in 17%, 3 or 4 in 18%, 5 or 6 in 13% and 7-12 in 10%. 50% of the patients had no PD activity in the ECU/TP tendons at baseline, while sum scores of PD was 1 in 12%, 2 in 13%, 3 or 4 in 13%, 5 or 6 in 9% and 7-9 in 4%. Both the sum score for GS and PD decreased significantly from baseline during follow-up (p&lt;0.01) and this was also found for DAS28 (ESR), CRP and assessor9s global VAS (p&lt;0.01). The table illustrates the improvements in US, clinical and laboratory assessments and the figure illustrates the sum scores of GS and PD during follow-up. <h3>Conclusions</h3> In this large US follow-up study on patients with established RA, tenosynovitis in ECU/TP tendons was found in three quarters of the patients, and the present study showed significant decrease in inflammation during treatment. Thus, examination of ECU and TP tendons is proposed to be included in follow-up studies with use of US on RA patients on biologic medication. <h3>Disclosure of Interest</h3> None declared
FRI0406 Small LDL-P Increases with Increased Disease Activity in SLE
Authors: L.J. Durcan, D. Winegar, M.A. Connelly, J. Otvos, L. Magder, M. Petri
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Systemic lupus erythematosus (SLE) associates with accelerated atherosclerotic cardiovascular (CV) disease which is not fully explained by traditional CV risk factors. Disease activity, prednisone treatment and immunologic abnormalities are also thought to contribute. Dyslipidemia is common in SLE patients, who have mild elevations in triglycerides (TG) and sometimes low HDL cholesterol levels. Recent evidence suggests that low density lipoprotein particle number (LDL-P) is a better marker of cardiovascular risk than LDL cholesterol levels. Lipoprotein subclass analyses have shown that SLE patients have larger VLDL particles and lower levels of large HDL particles compared to control subjects, but little is known about how these markers change with disease activity. <h3>Objectives</h3> We evaluated SLE patients during high disease activity and compared this to no or low disease activity to determine how lipoproteins change with active SLE. <h3>Methods</h3> Patients were identified as part of a prospective lupus cohort. At each visit, plasma samples were collected. Global disease activity was measured using the SLEDAI. Patients were included who had at least one visit with SLEDAI of 4+ (high disease activity) and one visit with SLEDAI≤3 (low disease activity). Plasma was analyzed for lipoprotein particle concentrations using nuclear magnetic resonance spectroscopy (NMR). The NMR spectrum also contains a signal termed GlycA derived from the carbohydrate chains of circulating acute phase glycoproteins that is a marker of systemic inflammation. Lipoprotein particle and GlycA levels were compared between high activity and no or low disease activity visits using t-tests. <h3>Results</h3> 33 patients met inclusion criteria (97% female, age range 19-76, 48% Caucasian and 48% African American). The mean number of visits per person with high Vs. low disease activity were 2.1 and 2.4 respectively. The total LDL particle number (LDL-P) and small LDL-P levels were higher with disease activity as was VLDL size (Table 1). Although GlycA levels were unchanged with active disease, they were higher than those described for healthy populations. <h3>Conclusions</h3> Although the lipoprotein profiles of SLE patients have been previously described, alterations in these profiles with disease activity have not been investigated. Here we demonstrate, for the first time in adult SLE, adverse changes in one novel lipid parameter (small LDL-P) with disease activity. Thus, we can now demonstrate one potential mechanism by which SLE disease activity influences atherosclerosis. <h3>Disclosure of Interest</h3> None declared
Psychotherapy
Authors: Jerome D. Frank
Journal: Psychotherapy and Psychosomatics (1978)

Research Articles| February 16 2010 Psychotherapy: Contemporary Trends in the United States Subject Area: Psychiatry and Psychology Jerome D. Frank Jerome D. Frank Baltimore Search for other works by this author on: This Site PubMed Google Scholar Psychother Psychosom (1978) 29 (1-4): 13–18. https://doi.org/10.1159/000287096 Article history Published Online: February 16 2010 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Jerome D. Frank; Psychotherapy: Contemporary Trends in the United States. Psychother Psychosom 31 December 1978; 29 (1-4): 13–18. https://doi.org/10.1159/000287096 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsPsychotherapy and Psychosomatics Search Advanced Search This content is only available via PDF. 1978Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Article PDF first page preview Close Modal You do not currently have access to this content.
Effect of Formaldehyde Wound Wash on Development of Local Wound Recurrences
Authors: Smith, Robert R., Gehan, Edmund A.
Journal: JNCI Journal of the National Cancer Institute (1959)

Journal Article Effect of Formaldehyde Wound Wash on Development of Local Wound Recurrences Get access Robert R. Smith, M.D., Robert R. Smith, M.D. Surgery Branch and Biometry Branch, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Edmund A. Gehan, Ph.D. Edmund A. Gehan, Ph.D. Surgery Branch and Biometry Branch, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 23, Issue 6, December 1959, Pages 1339–1345, https://doi.org/10.1093/jnci/23.6.1339 Published: 01 December 1959 Article history Received: 29 May 1959 Published: 01 December 1959
Techniques reduce contamination.
Authors:  Whitcomb,  Burke
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal